Sposoby nefarmakologicheskoy profilaktiki tromboembolicheskikh oslozhneniy u patsientov s fibrillyatsiey predserdiy1


Cite item

Full Text

About the authors

A. P Savchenko

НИИ кардиологии им А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва

I. V Zhirov

НИИ кардиологии им А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва

Yu. F Osmolovskaya

НИИ кардиологии им А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва

O. V Cherkavskaya

НИИ кардиологии им А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва

V. V Gramovich

НИИ кардиологии им А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва

E. V Dzybinskaya

НИИ кардиологии им А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва

S. N Tereshchenko

НИИ кардиологии им А.Л.Мясникова ФГБУ РКНПК Минздрава РФ, Москва

References

  1. Бокерия Л.А., Ревишвили А.Ш., Оганов Р.Г. и др. Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий. Вестн. аритмологии. 2010; 59: 53–77.
  2. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (19): 2369–429.
  3. ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104–23.
  4. Lip G, Nieuwlaat R, Pisters R et al. Refining Clinical Risk Stratification For Predicting Stroke and Tromboembolism in Atrial Fibrillation Using a Novel Risk Factor - based Approach The Euro Heart Survey on Atrial Fibrillation. CHEST 2010; 137: 263–72.
  5. Hart R.G., Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta - analysis. Ann Intern Med 1999; 131: 492–501.
  6. Hart R.G., Pearce L.A., Aguilar M.I. Meta - analysis: antitrombotic therapy to prevent stroke in patients who have non - valvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
  7. Fihn S.D., McDommel M, Matin D et al. Risk factors fоr complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow - up Study Groop Ann Intern Med 1993; 118 (7): 511–20.
  8. Gorter J.W. for the Stroke Prevention. Reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) study groups. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Neurology 1999; 53: 1319–27.
  9. ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: doi: 10.1161/CIR.0b013e31820f14c0
  10. Кропачева Е.С., Панченко Е.П. Практические аспекты терапии варфарином. Кардиология. 2005; 13 (19): 1246–9.
  11. Johnson W.D., Ganjoo A.K., Stone C.D. et al. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 2000; 15: 31–7.
  12. Al-Saady N.M., Obel O.A., Camm A.J. Left atrial appendage: structure, function, and role in tromboembolism. Heart 1999; 82: 547–54.
  13. Manning W.J. Atrial fibrillation, transesophageal echo, electrical cardioversion, and anticoagulation. Clin Cardiol 1995; 18 (58): 114.
  14. Whitlock R.P., Healey J.S., Connolly S.J. Left atrial appendage occlusion does not eliminate the need for warfarin. Circulation 2009; 120: 1927–32.
  15. Hanna I.R., Kolm P, Martin R et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO) six - month echocardiographic follow - up. J Am Coll Cardiol 2004; 43: 1868–72.
  16. Park J.W., Leithauser B, Gerk U et al. Percutaneous Left Atrial Appendage Transcatheter Occlusion (PLAATO) for stroke prevention in atrial fibrillation: 2-years outcome. J Invasive Cardiol 2009; 21 (9): 446–50.
  17. Block P.C., Burstein S, Casale P.N. et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year Results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. J Am Coll Cardiol Intv 2009; 2: 594–600.
  18. Sick P.B., Schuler G, Hauptmann K.E. et al. Initial Worldwide experience with the Watchman left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007; 49: 1490–5.
  19. Holmes D, Reddy V.Y., Turi Z et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non - inferiority trial. Lancet 2009; 374: 534–42.
  20. Reddy V.Y., Holmes D, Doshi S.K. et al. Safety of percutaneous left atrial appendage closure:results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011; 123: 417–24.
  21. Meier B, Palacios I, Windecker S et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003; 60: 417–22.
  22. Schmid M, Khattab A, Gloekler S, Meier B. Future Epidemic Impact of Atrial Fibrillation and a New Interventional Strategy for Stroke Prophylaxis. Future Cardiology 2011; 7 (2): 219–26.
  23. Plewka M, Kasprzak J.D., Peruga J.Z. et al. Left atrial appendage elimination using Amplatzer Cardiac Plug in patients with atrial fibrillation – report of two cases. Kardiol Pol 2011; 69 (1): 85–7.
  24. Lam Y.Y., Yip G.W., Yu C.M. et al. Left atrial appendage closure with Amplatzer cardiac plug for stroke prevention in atrial fibrillation: Initial Asia-Pacific experience. Catheter Cardiovasc Interv 2011; doi: 10.1002/ccd.23136
  25. Fontos G, Andréka P, Temesvári A et al. Percutaneous closure of left atrial appendage in non - valvular atrial fibrillation - international and Hungarian experiences. Orv Hetil 2010; 151 (18): 725–34.
  26. Clinical trial identifier NCT01118299. AMPLATZER Cardiac Plug Clinical Trial. History of Changes Last Updated on March 29, 2011; www.ClinicalTrials.gov
  27. Kamohara K, Fukamachi K, Ootaki Y et al. evaluation of a novel device for left atrial appendage exclusion: the second - generation atrial exclusion device. J Thorac Cardiovasc Surg 2006; 132: 340–6.
  28. Jayakar D, Goso F, Gomes E et al. Use of tissue welding technology to obliterate left atrial appendage – novel use of LigasureTM. Int Cardiovasc Thorac Surg 2005; 4: 372–3.
  29. Salzberg S.P., Gillinov A.M., Anyanwu A et al. Surgical left atrial appendage occlusion: evaluation of a novel device with magnetic resonance imaging. Eur J Cardiothorac Surg 2008; 7: 990–5.
  30. Lee R.J., Bartus K, Yakubov S.J. Catheter - based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: Initial experience in a canine model. Circ Cardiovasc Interv 2010; 3: 224–9.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies